한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제29권4호
  • /
  • Pages.247-253
  • /
  • 2019
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

급성 편두통 치료를 위한 글루탐산 수용체 길항제의 임상적 유효성에 대한 메타분석

Meta-analysis on the Efficacy of Glutamate Receptor Antagonists for Acute Migraine Treatment

  • 김선희 (경성대학교 약학대학 임상약학실험실) ;
  • 백인환 (경성대학교 약학대학 임상약학실험실)
  • 투고 : 2019.10.07
  • 심사 : 2019.11.07
  • 발행 : 2019.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Glutamate is implicated in the pathophysiology of migraine, a common neurological disorder. Therefore, glutamate receptor antagonists (GluRAs) have been suggested as a novel migraine treatment that are able to overcome the limitations of triptans. Objective: The aim of this study was to perform a meta-analysis to assess the efficacy of GluRAs for patients with migraine. Method: The PubMed, Cochrane Library, CINAHL, and Clinical Trial.gov databases were searched for randomized placebo-controlled trials of the efficacy of GluRAs for patients with migraine conducted up to August 2019. Two independent reviewers screened the literature according to inclusion and exclusion criteria and performed quality assessment and data extraction. Review Manager 5.3 software was used for the meta-analysis. Results: Three studies involving a total of 206 patients were included in the final analysis. Compared with placebo, GluRAs significantly improved the pain-free response at 2 hours (odds ratio [OR]=3.85, 95% confidence intervals [CIs]=1.63-9.09) and the 24-hour sustained pain freedom (OR=7.40; 95% CIs=2.36-23.20). The use of rescue medications with GluRAs was lower compared to that with placebo, but the difference was not significant (OR=0.39, 95% CI=0.10-1.47). Conclusion: Our meta-analysis showed that GluRAs were more effective than placebo for patients with migraine.

키워드

참고문헌

  1. Kim BK, Chu MK, Lee TG, et al. Prevalence and impact of migraine and tension-type headache in Korea. J Clin Neurol 2012;8:204-11. https://doi.org/10.3988/jcn.2012.8.3.204
  2. Kim SM, Ko YH, Yoon S, et al. Evidence-based clinical guideline for diagnosis and management of headache in Korea. Psychiatry Investig 2019;16(3):199-205. https://doi.org/10.30773/pi.2018.11.23
  3. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2012(2):CD008615.
  4. Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. SpringerPlus 2016;5;637. https://doi.org/10.1186/s40064-016-2211-8
  5. Chu MK. Diagnosis and treatment of migraine. Korean J Fam Med 2006;27:425-35.
  6. Chung CS. Drug therapy for migraine. J Korean Med Assoc 2007;50(10):917-23. https://doi.org/10.5124/jkma.2007.50.10.917
  7. Diener HC, Charles A, Goadsby PJ, et al. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015;14:1010-22. https://doi.org/10.1016/S1474-4422(15)00198-2
  8. Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. Drugs 2014;74:1165-76. https://doi.org/10.1007/s40265-014-0262-0
  9. Hoffmann J and Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics 2018;15:361-70. https://doi.org/10.1007/s13311-018-0616-5
  10. Andreou AP and Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18(6):789-803. https://doi.org/10.1517/13543780902913792
  11. Ferrari A, Rustichelli C, Baraldi C. Glutamate receptor antagonists with the potential for migraine treatment. Expert Opin Investig Drugs 2017; 06(12):1321-30.
  12. Monteith D, Jones RS, Verfaille SJ. Phase 2 trial of LY2300559 for treatment of acute migraine headaches. Cephalalgia 2013;33(11):981.
  13. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596-602. https://doi.org/10.1111/j.1468-2982.2004.00723.x
  14. Gomez-Mancilla B, Brand R, Jurgens TP, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 2014; 34(2):103-13. https://doi.org/10.1177/0333102413499648
  15. Waung MW, Akerman S, Wakefield M, et al. Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol 2016;3(8):560-71. https://doi.org/10.1002/acn3.302
  16. Lupi C, Benemei S, Guerzoni S, et al. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol 2019;15(3):189-98. https://doi.org/10.1080/17425255.2019.1578749
  17. Headache Classification Committee of the International Headache Society. The international classification of headache disorders (second edition). Cephalalgia 2004;24(Suppl 1):1-160.
  18. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 2019;39(6):687-710. https://doi.org/10.1177/0333102419828967
  19. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38. https://doi.org/10.1177/0333102411417901
  20. Kang H. Statistical considerations in meta-analysis, Hanyang Med Rev 2015;35:23-32. https://doi.org/10.7599/hmr.2015.35.1.23
  21. Kim SY, Park JE, Seo HJ, et al. NECA's guidance for undertaking systematic reviews and meta-analyses for intervention. Seoul: National Evidence-based Healthcare Collaborating Agengy 2011;129-99.